Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Osteogenic induction of mesenchymal stem cells (MSCs) refers to the process by which MSCs are stimulated to differentiate into osteoblasts, the bone-forming cells. This process is central to bone development, remodeling, and repair. MSCs are multipotent stromal cells capable of differentiating into various cell types including osteoblasts (bone), chondrocytes (cartilage), and adipocytes (fat). The process involves a complex interplay of signaling pathways (TGF-β/BMP, Wnt/β-catenin, SHH, FGF, EGFR, VEGFR), transcription factors (Runx2, Osterix), and metabolic shifts to drive gene expression necessary for bone formation.
Activation of intracellular signaling cascades (TGF-β/BMP, Wnt/β-catenin, SHH, FGF, EGFR, VEGFR) leading to the activation of transcription factors (Runx2, Osterix) and subsequent expression of osteogenic genes.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Osteogenic induction of mesenchymal stem cells (None).